|
Monday, October 15, 2007
Competitive Pressure
At the behest of Committee Chair Rep. Henry Waxman (D-CA), the House Committee on Oversight and Government Reform has produced a report on the wildly successful cost-reducing cost-inflating results of the private provision of the Medicare drug program (Medicare Pard D)
Findings of the report:
- The administrative expenses, sales costs, and profits of the privatized Part D program are almost six times higher than the administrative expenses of traditional Medicare.
- The rebates negotiated from drug manufacturers by the private Part D insurers will reduce Medicare drug spending by 8.1% in 2007. In contrast, the Medicaid program receives rebates from drug manufacturers that reduce drug spending by 26%, over three times as much.
- private insurers receive rebates from the drug manufacturers on purchases paid out-of-pocket by beneficiaries. In 2007, the Part D insurers are expected to receive $1.0 billion in drug rebates from transactions in which beneficiaries in coverage gaps pay 100% of the drug costs.
- In 2007, 59% of prescriptions filled by Medicare Part D will be filled with generic drugs. This level of use of generic drugs compares favorably with Medicaid, which fills 54% of prescriptions with generic drugs. It does not compare favorably with the experience of the Department of Veterans Affairs, which fills 68% of prescriptions with generic drugs.
 Note: Title is snark directed at David Broder's piece pimping the free market as a cure-all.
Posted by Craig Jennings
|